Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

IT seems every week there’s a new claim about what fat jabs can cure – beyond banishing that belly. The so-called skinny jabs – that were initially designed as treatment for type ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...